475 related articles for article (PubMed ID: 27182156)
1. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
Koido S; Okamoto M; Shimodaira S; Sugiyama H
Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
[TBL] [Abstract][Full Text] [Related]
3. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
4. Current immunotherapeutic approaches in pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Tsukinaga S; Mitobe J; Odahara S; Yukawa T; Matsudaira H; Nagatsuma K; Uchiyama K; Satoh K; Ito M; Komita H; Arakawa H; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2011; 2011():267539. PubMed ID: 21922022
[TBL] [Abstract][Full Text] [Related]
5. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
6. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies.
Yang J; Shangguan J; Eresen A; Li Y; Wang J; Zhang Z
Pathol Res Pract; 2019 Dec; 215(12):152691. PubMed ID: 31676092
[TBL] [Abstract][Full Text] [Related]
8. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
9. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
10. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
13. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
[TBL] [Abstract][Full Text] [Related]
16. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
Front Immunol; 2019; 10():1832. PubMed ID: 31440238
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
[TBL] [Abstract][Full Text] [Related]
18. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
[TBL] [Abstract][Full Text] [Related]
19. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
[TBL] [Abstract][Full Text] [Related]
20. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Li J; Yuan S; Norgard RJ; Yan F; Yamazoe T; Blanco A; Stanger BZ
Cancer Immunol Res; 2020 Mar; 8(3):282-291. PubMed ID: 31871120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
